China’s biotech sector is entering a rapid growth phase. The U.S. FDA has loosened its rules, now accepting a single pivotal trial plus confirmatory data for new‑drug approval, a move that shortens development time and cuts costs. This change helped Moderna quickly revise and re‑file its quadrivalent mRNA flu vaccine (mRNA‑1010), securing an August 5, 2026 review deadline and boosting commercial confidence. At the same time, several Chinese companies have earned IND clearance for mRNA cancer vaccines—Niuanjin Bio’s personalized R01, Likang Life’s LK101, and Yuekang Bio’s universal YKYY031—signaling a surge in home‑grown innovation. European regulators have also approved Hanssen Pharma’s lung‑cancer drug almetinib for patients with specific EGFR mutations, expanding treatment options. Chinese firms are striking massive partnership deals. AbbVie pledged $650 million upfront (potentially $5.6 billion) for Rongchang Bio’s PD‑1/VEGF bispecific antibody. AstraZeneca committed $1.2 billion upfront (up to $18.5 billion) for Shiyao Group’s once‑monthly GLP‑1R/GIPR agonist. Pfizer and GSK have each signed multi‑hundred‑million‑dollar collaborations for siRNA and antibody platforms. The overall trend shows Chinese innovators shifting from simple product licensing to exporting technology and co‑developing globally, attracting deep‑pocket multinational interest.
Read moreChina is rolling out a new long‑term care insurance system in Sichuan, aiming to launch a pilot in 2026 and have a full‑scale program by 2027, with a multi‑layered safety net expected by 2028. At the same time, Chinese researchers achieved a world‑first by using a six‑gene‑edited pig liver in an extracorporeal perfusion device to treat a patient with liver failure, showing promising safety and effectiveness for future transplant bridges. Across the Pacific, scientists from the University of Pennsylvania and Harvard have created an electronic implant that can both monitor and steer the maturation of human pancreatic islet cells, a breakthrough that could pave the way for cell‑based diabetes cures. Meanwhile, Japan is seeing a rise in measles cases, with 43 new infections reported in the first seven weeks of the year, prompting health officials to alert anyone who may have crossed paths with patients to seek care if symptoms appear. In South America, Uruguay has declared a health emergency as avian influenza spreads among birds, heightening concerns over potential human transmission.
Read more